Avience Biomedicals Limited (NSE:AVIENCE)
India · Delayed Price · Currency is INR 346.80
+10.45 (3.11%)
At close: Sep 10, 2026
Avience Biomedicals Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | 29.34 | 49.37 | 3.57 | 2.45 | 0.25 |
Cash & Short-Term Investments | 29.34 | 49.37 | 3.57 | 2.45 | 0.25 |
Cash Growth | -40.56% | 1283.55% | 45.77% | 883.44% | -64.55% |
Accounts Receivable | 210.17 | 172.12 | 80.91 | 18.07 | 25.3 |
Other Receivables | 1.51 | 0.9 | 0.6 | 0.07 | - |
Receivables | 264.29 | 176.12 | 84.1 | 20.21 | 25.3 |
Inventory | 171.75 | 130.71 | 123.95 | 35.44 | 14.69 |
Prepaid Expenses | - | 1.66 | 0.06 | 0.04 | - |
Other Current Assets | - | 13.89 | 18.73 | 10.68 | 5.38 |
Total Current Assets | 465.39 | 371.73 | 230.4 | 68.81 | 45.61 |
Property, Plant & Equipment | 287.69 | 176.14 | 101.46 | 25.18 | 11.63 |
Long-Term Investments | 0.28 | 0.51 | 2.88 | 1.12 | - |
Goodwill | 1.45 | 1.45 | 1.45 | - | - |
Long-Term Deferred Tax Assets | 0.35 | 0.74 | 1.08 | - | - |
Other Long-Term Assets | 24.29 | 14.68 | 9.24 | 5.03 | 3.68 |
Total Assets | 779.44 | 565.25 | 346.51 | 100.15 | 60.93 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Accounts Payable | 94.75 | 72.68 | 55.49 | 12.72 | 2.29 |
Accrued Expenses | 33.46 | 10.11 | 5.21 | 1.19 | 0.86 |
Short-Term Debt | 157.06 | 114.99 | 69.75 | 24.87 | 23.18 |
Current Portion of Long-Term Debt | - | 8.1 | 8.71 | 0.21 | - |
Current Income Taxes Payable | - | 23.88 | 6.63 | 0.59 | 0.81 |
Current Unearned Revenue | - | 1.5 | 1.5 | - | - |
Other Current Liabilities | 44.3 | 3.08 | 60.72 | 17.76 | 3.8 |
Total Current Liabilities | 329.57 | 234.33 | 208.02 | 57.34 | 30.94 |
Long-Term Debt | 132.29 | 98.5 | 72.84 | 1.49 | 1.7 |
Pension & Post-Retirement Benefits | - | 2.25 | 2.18 | - | 0.02 |
Long-Term Deferred Tax Liabilities | 1.86 | 1.49 | 1.19 | 0.54 | 0.21 |
Other Long-Term Liabilities | 1.6 | 0.16 | 0 | 0.1 | 0.14 |
Total Liabilities | 465.31 | 336.72 | 284.23 | 59.47 | 33.01 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Common Stock | 40.31 | 40.31 | 32.85 | 32.85 | 20.35 |
Additional Paid-In Capital | - | 85.88 | - | - | - |
Retained Earnings | - | 102.34 | 29.43 | 7.83 | 7.58 |
Comprehensive Income & Other | 273.81 | -0 | - | - | - |
Shareholders' Equity | 314.13 | 228.53 | 62.28 | 40.68 | 27.92 |
Total Liabilities & Equity | 779.44 | 565.25 | 346.51 | 100.15 | 60.93 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Total Debt | 289.35 | 221.58 | 151.31 | 26.57 | 24.88 |
Net Cash (Debt) | -260 | -172.22 | -147.74 | -24.12 | -24.64 |
Net Cash Growth | - | - | - | - | - |
Net Cash Per Share | -64.49 | -45.39 | -44.98 | -9.04 | -18.31 |
Filing Date Shares Outstanding | 4.03 | 4.03 | 3.28 | 3.28 | 2.64 |
Total Common Shares Outstanding | 4.03 | 4.03 | 3.28 | 3.28 | 2.64 |
Working Capital | 135.82 | 137.4 | 22.38 | 11.47 | 14.67 |
Book Value Per Share | 77.91 | 56.69 | 18.96 | 12.38 | 10.59 |
Tangible Book Value | 312.68 | 227.08 | 60.83 | 40.68 | 27.92 |
Tangible Book Value Per Share | 77.56 | 56.33 | 18.52 | 12.38 | 10.59 |
Land | - | 45.74 | 40.99 | - | - |
Machinery | - | 112.31 | 84.18 | 28.32 | 12.68 |
Construction In Progress | - | 46.19 | 0.28 | - | - |